2D and 3D similarity landscape analysis identifies PARP as a novel off-target for the drug Vatalanib

BackgroundSearching for two-dimensional (2D) structural similarities is a useful tool to identify new active compounds in drug-discovery programs. However, as 2D similarity measures neglect important structural and functional features, similarity by 2D might be underestimated. In the present study, we used combined 2D and three-dimensional (3D) similarity comparisons to reveal possible new functions and/or side-effects of known bioactive compounds.ResultsWe utilised more than 10,000 compounds from the SuperTarget database with known inhibition values for twelve different anti-cancer targets. We performed all-against-all comparisons resulting in 2D similarity landscapes. Among the regions with low 2D similarity scores are inhibitors of vascular endothelial growth factor receptor (VEGFR) and inhibitors of poly ADP-ribose polymerase (PARP). To demonstrate that 3D landscape comparison can identify similarities, which are untraceable in 2D similarity comparisons, we analysed this region in more detail. This 3D analysis showed the unexpected structural similarity between inhibitors of VEGFR and inhibitors of PARP. Among the VEGFR inhibitors that show similarities to PARP inhibitors was Vatalanib, an oral “multi-targeted” small molecule protein kinase inhibitor being studied in phase-III clinical trials in cancer therapy. An in silico docking simulation and an in vitro HT universal colorimetric PARP assay confirmed that the VEGFR inhibitor Vatalanib exhibits off-target activity as a PARP inhibitor, broadening its mode of action.ConclusionIn contrast to the 2D-similarity search, the 3D-similarity landscape comparison identifies new functions and side effects of the known VEGFR inhibitor Vatalanib.

[1]  John P. Overington,et al.  ChEMBL: a large-scale bioactivity database for drug discovery , 2011, Nucleic Acids Res..

[2]  Yoshihiro Yamanishi,et al.  Drug Side-Effect Prediction Based on the Integration of Chemical and Biological Spaces , 2012, J. Chem. Inf. Model..

[3]  M. Dowsett,et al.  Biological Evidence for Dual Antiangiogenic-Antiaromatase Activity of the VEGFR Inhibitor PTK787/ZK222584 In vivo , 2010, Clinical Cancer Research.

[4]  Philip E. Bourne,et al.  PROMISCUOUS: a database for network-based drug-repositioning , 2010, Nucleic Acids Res..

[5]  A. Rademaker,et al.  A phase II trial of PTK787/ZK 222584 in recurrent or progressive radiation and surgery refractory meningiomas , 2014, Journal of Neuro-Oncology.

[6]  E. Rogakou,et al.  DNA Double-stranded Breaks Induce Histone H2AX Phosphorylation on Serine 139* , 1998, The Journal of Biological Chemistry.

[7]  J. Medina-Franco,et al.  Shifting from the single to the multitarget paradigm in drug discovery. , 2013, Drug discovery today.

[8]  J. Mestres,et al.  A ligand-based approach to mining the chemogenomic space of drugs. , 2008, Combinatorial chemistry & high throughput screening.

[9]  Naomie Salim,et al.  Analysis and Display of the Size Dependence of Chemical Similarity Coefficients , 2003, J. Chem. Inf. Comput. Sci..

[10]  Eric Masson,et al.  Phase I study of the safety, tolerability, pharmacokinetics, and pharmacodynamics of PTK787/ZK 222584 administered twice daily in patients with advanced cancer. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[11]  John M. Barnard,et al.  Chemical Similarity Searching , 1998, J. Chem. Inf. Comput. Sci..

[12]  K Jarnagin,et al.  Novel inhibitors of poly(ADP-ribose) polymerase/PARP1 and PARP2 identified using a cell-based screen in yeast. , 2001, Cancer research.

[13]  Brian K. Shoichet,et al.  ZINC - A Free Database of Commercially Available Compounds for Virtual Screening , 2005, J. Chem. Inf. Model..

[14]  Robert B. Russell,et al.  SuperTarget and Matador: resources for exploring drug-target relationships , 2007, Nucleic Acids Res..

[15]  A Macchiarulo,et al.  Modeling of poly(ADP-ribose)polymerase (PARP) inhibitors. Docking of ligands and quantitative structure-activity relationship analysis. , 2001, Journal of medicinal chemistry.

[16]  D J Diller,et al.  High throughput docking for library design and library prioritization , 2001, Proteins.

[17]  W. Bonner,et al.  Histone 2A, a heteromorphous family of eight protein species. , 1980, Biochemistry.

[18]  P. Willett,et al.  A Comparison of Some Measures for the Determination of Inter‐Molecular Structural Similarity Measures of Inter‐Molecular Structural Similarity , 1986 .

[19]  David Rogers,et al.  Extended-Connectivity Fingerprints , 2010, J. Chem. Inf. Model..

[20]  P. Bork,et al.  Network Neighbors of Drug Targets Contribute to Drug Side-Effect Similarity , 2011, PloS one.

[21]  James H. Doroshow,et al.  Histone γH2AX and Poly(ADP-Ribose) as Clinical Pharmacodynamic Biomarkers , 2010, Clinical Cancer Research.

[22]  L Xue,et al.  Searching for molecules with similar biological activity: analysis by fingerprint profiling. , 2000, Pacific Symposium on Biocomputing. Pacific Symposium on Biocomputing.

[23]  Jürgen Bajorath,et al.  Selected Concepts and Investigations in Compound Classification, Molecular Descriptor Analysis, and Virtual Screening , 2001, J. Chem. Inf. Comput. Sci..

[24]  Vladimir Poroikov,et al.  PASS: prediction of activity spectra for biologically active substances , 2000, Bioinform..

[25]  Yanli Wang,et al.  PubChem: a public information system for analyzing bioactivities of small molecules , 2009, Nucleic Acids Res..

[26]  E. Voest,et al.  Target practice: lessons from phase III trials with bevacizumab and vatalanib in the treatment of advanced colorectal cancer. , 2007, The oncologist.

[27]  Z. Darżynkiewicz,et al.  Cytometric assessment of histone H2AX phosphorylation: a reporter of DNA damage. , 2006, Methods in molecular biology.

[28]  James C Paulson,et al.  Glycan fingerprints: calculating diversity in glycan libraries. , 2012, ACS chemical biology.

[29]  John P. Overington,et al.  Can we rationally design promiscuous drugs? , 2006, Current opinion in structural biology.

[30]  W. Kabsch.  A solution for the best rotation to relate two sets of vectors , 1976 .

[31]  Martin Thimm,et al.  Comparison of 2D Similarity and 3D Superposition. Application to Searching a Conformational Drug Database , 2004, J. Chem. Inf. Model..

[32]  Olivier Michielin,et al.  Shaping the interaction landscape of bioactive molecules , 2013, Bioinform..

[33]  Krystyna J. Dillon,et al.  A FlashPlate Assay for the Identification of PARP-1 Inhibitors , 2003, Journal of biomolecular screening.

[34]  A. Armstrong,et al.  A phase Ib study of combined VEGFR and mTOR inhibition with vatalanib and everolimus in patients with advanced renal cell carcinoma. , 2014, Clinical genitourinary cancer.

[35]  Beáta Flachner,et al.  Combination of 2D/3D Ligand-Based Similarity Search in Rapid Virtual Screening from Multimillion Compound Repositories. Selection and Biological Evaluation of Potential PDE4 and PDE5 Inhibitors , 2014, Molecules.

[36]  M. Zvelebil,et al.  The vascular endothelial growth factor receptor inhibitor PTK787/ZK222584 inhibits aromatase. , 2009, Cancer research.

[37]  J. Mestan,et al.  PTK787/ZK 222584, a novel and potent inhibitor of vascular endothelial growth factor receptor tyrosine kinases, impairs vascular endothelial growth factor-induced responses and tumor growth after oral administration. , 2000, Cancer research.

[38]  H. L. Morgan.  The Generation of a Unique Machine Description for Chemical Structures-A Technique Developed at Chemical Abstracts Service. , 1965 .

[39]  A. Rottmann,et al.  Metabolism and Disposition of Vatalanib (PTK787/ZK-222584) in Cancer Patients , 2006, Drug Metabolism and Disposition.

[40]  Philip E. Bourne,et al.  SuperTarget goes quantitative: update on drug–target interactions , 2011, Nucleic Acids Res..

[41]  S. Giordano,et al.  From single- to multi-target drugs in cancer therapy: when aspecificity becomes an advantage. , 2008, Current medicinal chemistry.

[42]  H. Friedman,et al.  Phase I pharmacokinetic study of the vascular endothelial growth factor receptor tyrosine kinase inhibitor vatalanib (PTK787) plus imatinib and hydroxyurea for malignant glioma , 2009, Cancer.